Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
NCT02915523 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
- Lead sponsor
- Syndax Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 19, 2016
- Completion date
- April 21, 2021
- Enrollment
- 140 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer